Partnering plays a key role in Agennix’s strategy.

Agennix is focused on developing novel therapies to improve the length and quality of life of seriously ill patients in areas of major unmet medical need. Agennix is seeking one or more international partners for oral talactoferrin.

The Company is focused on pharmaceutical companies and large biotechnology firms with a strong presence in the area of critical care and/or cancer development and commercialization.

For further information on Agennix's approach to partnering and current opportunities, please contact:

Business Development

This e-mail address is being protected from spambots. You need JavaScript enabled to view it